1. GSK aims to make 1B doses of vaccine booster for multiple COVID-19 partners — Protalix and Chiesi get close to potential Fabry disease treatment approval — AstraZeneca locks up COVID-19 vaccine supply with Oxford BioMedica deal — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Otonomy, The Truth

Discussion in 'Otonomy' started by anonymous, Mar 4, 2017 at 8:21 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    I have never posted on here before but I feel an obligation to warn anyone that might be thinking about a "career" with this company. Please run away from them like you have never ran before. The executive team is one of the worst in the industry and they continue to double down, even triple down, on a loosing hand, which is their strategy to market. The product is over priced you idiots!! The sad thing is how they have treated the people that have worked so hard to try to polish the turd Otiprio!! Investors, pull your money before Dave Weber, Dina Lynch, and David Kaplan piss the last remaining few million they have left down the drain.
     

  2. anonymous

    anonymous Guest

    Great post!! The level of incompetence at this company is just incredible. Wasted millions and millions of dollars on the worst product launch in history.
     
  3. anonymous

    anonymous Guest

    The most amazing part of the story is that the board didn't scuttle the entire operation and left these losers to waste more investor money. I'm sure some more promotions are in order for the access team.
     
  4. anonymous

    anonymous Guest

    First time poster here. I can attest to the above comments. I was at this company from very early on and can say that the launch strategy and the strategy they continue to follow (reimbursement through C and now J code) is ridiculous. Most of these procedures are reimbursed in a bundled/capitated setting so no matter what code you have or use you will not get separate reimbursement. The issue is PRICE. The product is priced way too high.
    This strategy will also be used if/when they get swimmer's ear indication but I can tell you that insurers will not pay $300 to treat swimmer's ear.